Keeps Biopharma킵스파마
256940 · KOSDAQ · ₩256940 · 킵스파마
₩5,490▲ ₩220 (4.17%)End-of-day · Oct 27, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩170B | ₩128B | ₩92B | ₩15B | ₩4.3B |
| Cost of sales | ₩133B | ₩110B | ₩79B | ₩14B | ₩5B |
| Gross profit | ₩38B | ₩17B | ₩13B | ₩1B | −₩789M |
| Operating income | ₩1.6B | ₩6.2B | ₩3.1B | −₩8.6B | −₩12B |
| Net income | −₩10B | ₩1.6B | ₩3.5B | −₩12B | −₩16B |
| Net income to shareholders | −₩9.8B | ₩1.1B | ₩3.9B | −₩11B | −₩15B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩234B | ₩165B | ₩117B | ₩86B | ₩93B |
| Current assets | ₩102B | ₩71B | ₩47B | ₩43B | ₩63B |
| Cash and equivalents | ₩22B | ₩19B | ₩4.1B | ₩24B | ₩37B |
| Total liabilities | ₩152B | ₩102B | ₩59B | ₩33B | ₩33B |
| Current liabilities | ₩89B | ₩85B | ₩56B | ₩32B | ₩30B |
| Borrowings | ₩92B | ₩55B | ₩48B | ₩28B | ₩27B |
| Total equity | ₩82B | ₩63B | ₩59B | ₩52B | ₩61B |
| Shareholders' equity | ₩62B | ₩50B | ₩57B | ₩53B | ₩61B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩15B | ₩4.8B | −₩57M | −₩866M | −₩8.4B |
| Capital spending | ₩32B | ₩6.6B | ₩991M | ₩96M | ₩91M |
| Free cash flow | −₩47B | −₩1.8B | −₩1B | −₩962M | −₩8.5B |
Consolidated where available. Amounts in won.
Also known as: Keeps Biopharma / 킵스파마 / 256940 / KRX:256940
Source: KRX statistical information